Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 7, 2011Clinical Cancer ResearchOpen Access

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

ELEvan J. LipsonJohns Hopkins University
Charles G. Drake
Charles G. DrakeUniversité Paris-Sud

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lipson et al. (2011) studied this question.

synapsesocial.com/papers/6a6e418ff44fa9f079dc1212https://doi.org/10.1158/1078-0432.ccr-11-1595
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-21998 · 489 citations
  2. 2Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting2010 · 422 citations
  3. 3Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma2008 · 466 citations
  4. 4Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma2011 · 4,539 citations